Hebang Biotech announced that the controlling shareholder of the company, Hebang Group, released the pledge of 218 million shares on September 9, 2026, accounting for 11.10% of its shares and 2.47% of the company's total share capital; the same amount of shares was pledged to Chongqing Rural Commercial Bank Liangjiang Branch on the same day. The pledge period is until September 8, 2029, for financing purposes required for production and operation. As of the disclosure date, Hebang Group held 1,964 million shares of the company, accounting for 22.24% of the total share capital, and pledged a total of 1,279 billion shares, accounting for 65.13% of its shares and 14.48% of its total share capital; Hebang Group and co-actor He Zhenggang held a total of 2,376 billion shares, accounting for 26.91% of the total share capital, and pledged 1,279 billion shares, accounting for 53.82% of its total share capital.

Hebang Biotech announced that the controlling shareholder of the company, Hebang Group, released the pledge of 218 million shares on September 9, 2026, accounting for 11.10% of its shares and 2.47% of the company's total share capital; the same amount of shares was pledged to Chongqing Rural Commercial Bank Liangjiang Branch on the same day. The pledge period is until September 8, 2029, for financing purposes required for production and operation. As of the disclosure date, Hebang Group held 1,964 million shares of the company, accounting for 22.24% of the total share capital, and pledged a total of 1,279 billion shares, accounting for 65.13% of its shares and 14.48% of its total share capital; Hebang Group and co-actor He Zhenggang held a total of 2,376 billion shares, accounting for 26.91% of the total share capital, and pledged 1,279 billion shares, accounting for 53.82% of its total share capital.